C. Cox

Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma

C. Hurt, P. Allavena, A. Mantovani, 2021, npj Precision Oncology.

Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.

C. Hurt, M. Hingorani, G. Radhakrishna, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

H. Grabsch, Ricky A. Sharma, T. Crosby, 2021, European journal of cancer.

Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study

C. Hurt, M. Strachan, L. Moss, 2020, European Thyroid Journal.

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

H. Grabsch, C. Hurt, Ricky A. Sharma, 2020 .

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

R. Butler, C. Twelves, R. Venkitaraman, 2020, The Lancet. Oncology.

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer

C. Hurt, E. O’Neill, A. Abraham, 2020, British Journal of Cancer.